Unmet needs in the treatment of idiopathic pulmonary fibrosis―insights from patient chart review in five European countries
Two antifibrotic drugs, pirfenidone and nintedanib, are approved by the European Medicines Agency and the US Food and Drug Administration for the treatment of idiopathic pulmonary fibrosis (IPF). In this analy...
BMC Pulmonary Medicine 2017 17:124
Published on: 15 September 2017